Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, T6G 1Z2, Canada.
Immunotherapy. 2021 Dec;13(17):1407-1417. doi: 10.2217/imt-2021-0068. Epub 2021 Oct 28.
To analyze tumor- and treatment-related factors that might impact the development of certain adverse events (AEs) of potential immune etiology among patients receiving PD-L1 inhibitors. The FDA Adverse Event Reporting System (FAERS) was accessed, and AE reports related to the use of PD-L1 inhibitors were reviewed. Associations between treatment, tumor type and occurrence of AEs of special interest were analyzed through multivariable logistic regression analysis. A total of 80,304 AE reports were included in the current analysis. Diagnosis with lung cancer was associated with a higher probability of pneumonitis; diagnosis with melanoma was associated with a higher probability of hepatitis, hypophysitis/hypopituitarism and uveitis; and diagnosis with genitourinary cancers was associated with a higher probability of nephritis, adrenal insufficiency and myocarditis. Within this cohort limited to AEs reported to the FAERS, there is an association between different AEs of special interest, agent(s) used and tumor(s) treated.
分析可能影响接受 PD-L1 抑制剂治疗的患者出现某些潜在免疫病因的不良事件（AE）的肿瘤和治疗相关因素。访问了 FDA 不良事件报告系统（FAERS），并审查了与 PD-L1 抑制剂使用相关的 AE 报告。通过多变量逻辑回归分析，分析了治疗、肿瘤类型与特殊关注的 AE 发生之间的关联。当前分析共纳入 80304 例 AE 报告。肺癌诊断与肺炎的发生概率更高相关；黑色素瘤诊断与肝炎、垂体炎/垂体功能减退和葡萄膜炎的发生概率更高相关；而泌尿生殖系统癌症的诊断与肾炎、肾上腺功能不全和心肌炎的发生概率更高相关。在 FAERS 报告的仅限于 AE 的这个队列中，不同的特殊关注 AE、使用的药物和治疗的肿瘤之间存在关联。
